Nabiximols

Drug Profile

Nabiximols

Alternative Names: Cannabidiol/tetrahydrocannabinol; CBD/THC; CBD:THC; Delta-9-tetrahydrocannabinol/cannabidiol; Delta-9-THC/cannabidiol; Dronabinol/cannabidiol; GW 1000; GW-1000-02; Medicinal cannabis - GW Pharmaceuticals; Nabidiolex®/Tetranabinex®; Sativex; Tetrahydrocannabinol/cannabidiol; THC/CBD; THC:CBD

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GW Pharmaceuticals
  • Developer Almirall S.A.; GW Pharmaceuticals; Novartis; Otsuka Pharmaceutical
  • Class Analgesics; Antiemetics; Anxiolytics; Appetite stimulants; Cannabinoids; Muscle relaxants; Neuroprotectants; Phytotherapies
  • Mechanism of Action Antioxidants; Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Muscle spasticity; Neuropathic pain
  • Phase I/II Glioblastoma
  • No development reported Bladder dysfunction; Stomatitis

Most Recent Events

  • 01 Mar 2017 GW Pharmaceuticals completes a phase III trial in Muscle spasticity (Adjunctive treatment, In adolescents, In children) in United Kingdom, Czech Republic, Israel (Buccal) (NCT01898520)
  • 07 Feb 2017 Nabiximols receives Orphan Drug status for Glioma in European Union before February 2017
  • 07 Feb 2017 Efficacy and adverse events data from the phase II part of a phase I/II trial in Glioblastoma released by GW Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top